Does methylnaltrexone reduce the incidence and severity of itch following spinal anaesthesia with intrathecal morphine in women undergoing caesarean delivery.
In women receiving spinal anaesthesia including intrathecal morphine for caesarean section, is subcutaneous methylnaltrexone 12 mg given at the end of surgery more effective than placebo in reducing 24 hour pruritus severity?
King Edward Memorial Hospital for Women
130 participants
Jun 12, 2012
Interventional
Conditions
Summary
This randomised clinical trial is investigating the preventive effect of subcutaneous methylnaltrexone, in comparison with placebo, on the severity of pruritus in women receiving spinal anaesthesia including intrathecal morphine for caesarean section.
Eligibility
Inclusion Criteria2
- American Society of Anesthesiologists classification 1 or 2
- Elective caesarean section under spinal anaesthesia, with or without epidural catheterization
Exclusion Criteria9
- Preoperative use of opioid medication
- Contraindication to spinal anaesthesia
- Preoperative pruritus for any reason
- Weight outside the range 62-114 kg
- Severe renal impairment, gastro-intestinal disease or diarrhoea
- Conversion to another method of anaesthesia, prior to study drug, for any reason
- Failure to administer intrathecal morphine
- Administration of a drug with anti-pruritic activity (propofol, antihistamine, 5HT3-receptor antagonists or other drugs with opioid agonist or antagonist activity such as tramadol or naloxone) prior to study drug
- Administration of epidural opioid prior to administration of study drug.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The study drug will be 12 mg methylnaltrexone (MNTX) in 0.6 ml solution for subcutaneous injection into the anaesthetised anterolateral thigh at the completion of surgery.
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000572864